Market Research Logo

Commercial Interests at AACR 2017 - A 1stOncology Insights Report

Commercial Interests at AACR 2017 - A 1stOncology Insights Report

This report is a unique guide to understanding and evaluating the positions of the cancer drugs and companies presented at the AACR 2017 Annual Meeting.

This leading event in the oncology drug developers calender represents some of the very best in cancer science and this report allows the reader to review the meeting through the lens of 17 “hot” areas in oncology. As such, it is a must read for anyone with an interest in oncology and who wants a full picture of the landscape of drug development emerging from AACR 2017.

With more than 6,500+ abstracts presented at AACR 2017, this report allows you to break down this mountain of information to reveal the positions of the more than 470 commercial drugs with published abstracts by their own innovating companies or partners. These drugs represent the core of what is happening in cancer drug development today and this report reveals where they are positioned in 17 ""hot"" areas in oncology, including:

  • Start-Ups ()
  • Fierce 15 Drugs ()
  • Orphan Drugs ()
  • Breakthrough Therapies ()
  • Cancer Vaccines ()
  • CAR/TCR Therapies (14)
  • Immune Checkpoints ()
  • Epigenetic Therapies ()
  • Protein Kinase Inhibitors ()
  • Antibodies in Oncology ()
  • Cancer Peptides ()
  • Nucleic Acid Therapies ()
  • Conjugated Drugs ()
Area (Number of Drugs in Each Area)

The AACR Annual Meeting is one of the events that shapes the direction of commercial drug development in oncology. Use this report to understand from a trustworthy third-party the position, strengths, weaknesses and recent successes and failures of the drugs represented at this years meeting in an executive and easy to understand format.

It includes almost XXX references detailing the latest positive and negative pipeline development for circa YYY top cancer drugs throughout 2016 to present, giving you a comprehensive insight to current developments such as successful clinical trials, trials with missed primary endpoints, new or terminated partnerships, M&A and much more.


1 Executive Summary
2 About 1stOncology™ Insights
2.1 Scope and Methodology
3 Table of Contents
3.1 List of Figures
3.2 List of Tables
4 Major Recent Developments on Cancer Drugs at AACR from 2016 to Present
4.1 Positive Highlights on Cancer Drugs by Highest Stage
4.1.1 Marketed
4.1.2 Pre-registration
4.1.3 Phase III
4.1.4 Phase II
4.1.5 Phase I
4.1.6 Preclinical
4.1.7 Discovery
4.2 Negative Highlights on Cancer Drugs by Highest Stage
4.2.1 Marketed
4.2.2 Pre-registration
4.2.3 Phase III
4.2.4 Phase II
5 Overview of Cancer Drugs at AACR 2017
5.1 Pipeline Breakdown and Status
5.2 From Small Molecules to Biologics
5.3 Analysis of the Drug Target Landscape
5.4 Pursued Tumor Types
5.5 Biomarkers and Combination Therapies Review
5.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
5.7 Drug Innovators
6 AACR 2017 by Startups
6.1 Pipeline Breakdown and Status
6.2 Compound Review
6.3 Target Analysis
6.4 Pursued Tumor Types
6.5 Biomarkers and Combination Therapies Review
6.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
6.7 Drug Innovators
7 AACR 2017 by Fierce 15 Companies
7.1 Pipeline Breakdown and Status
7.2 Compound Review
7.3 Target Analysis
7.4 Pursued Tumor Types
7.5 Biomarkers and Combination Therapies Review
7.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
7.7 Drug Innovators
8 AACR 2017 by Orphan Drugs
8.1 Pipeline Breakdown and Status
8.2 Compound Review
8.3 Target Analysis
8.4 Pursued Tumor Types
8.5 Biomarkers and Combination Therapies Review
8.6 Breakthrough Drugs and Sales Data Figures
8.7 Drug Innovators
9 AACR 2017 by Breakthrough Therapies
9.1 Pipeline Breakdown and Status
9.2 Compound Review
9.3 Target Analysis
9.4 Pursued Tumor Types
9.5 Biomarkers and Combination Therapies Review
9.6 Orphan Drugs and Sales Data Figures
9.7 Drug Innovators
10 AACR 2017 by Cancer Vaccines
10.1 Pipeline Breakdown and Status
10.2 Compound Review
10.3 Target Analysis
10.4 Pursued Tumor Types
10.5 Biomarkers and Combination Therapies Review
10.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
10.7 Drug Innovators
11 AACR 2017 by CAR/TCR Therapies
11.1 Pipeline Breakdown and Status
11.2 Compound Review
11.3 Target Analysis
11.4 Pursued Tumor Types
11.5 Biomarkers and Combination Therapies Review
11.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
11.7 Drug Innovators
12 AACR 2017 by Immune Checkpoint Drugs
12.1 Pipeline Breakdown and Status
12.2 Compound Review
12.3 Target Analysis
12.4 Pursued Tumor Types
12.5 Biomarkers and Combination Therapies Review
12.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
12.7 Drug Innovators
13 AACR 2017 by Epigenetic Therapies
13.1 Pipeline Breakdown and Status
13.2 Compound Review
13.3 Target Analysis
13.4 Pursued Tumor Types
13.5 Biomarkers and Combination Therapies Review
13.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
13.7 Drug Innovators
14 AACR 2017 by DNA Damage Response Drugs
14.1 Pipeline Breakdown and Status
14.2 Compound Review
14.3 Target Analysis
14.4 Pursued Tumor Types
14.5 Biomarkers and Combination Therapies Review
14.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
14.7 Drug Innovators
15 AACR 2017 by Protein Kinase Inhibitors
15.1 Pipeline Breakdown and Status
15.2 Compound Review
15.3 Target Analysis
15.4 Pursued Tumor Types
15.5 Biomarkers and Combination Therapies Review
15.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
15.7 Drug Innovators
16 AACR 2017 by Antibody Drugs
16.1 Pipeline Breakdown and Status
16.2 Target Analysis
16.3 Pursued Tumor Types
16.4 Biomarkers and Combination Therapies Review
16.5 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
16.6 Drug Innovators
17 AACR 2017 by Peptide Drugs
17.1 Pipeline Breakdown and Status
17.2 Target Analysis
17.3 Pursued Tumor Types
17.4 Biomarkers and Combination Therapies Review
17.5 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
17.6 Drug Innovators
18 AACR 2017 by Nucleic Acid Therapies
18.1 Pipeline Breakdown and Status
18.2 Target Analysis
18.3 Pursued Tumor Types
18.4 Biomarkers and Combination Therapies Review
18.5 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
18.6 Drug Innovators
19 AACR 2017 by Conjugated Drugs
19.1 Pipeline Breakdown and Status
19.2 Compound Review
19.3 Target Analysis
19.4 Pursued Tumor Types
19.5 Biomarkers and Combination Therapies Review
19.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
19.7 Drug Innovators
20 Disclaimer
21 Drug Index
22 Drug Innovator Index
1.1 List of Figures
Figure 1: Pipeline Breakdown and Status of Cancer Drugs at AACR 2017
Figure 2: Compound Review of Cancer Drugs at AACR 2017
Figure 3: Target Analysis of Cancer Drugs at AACR 2017
Figure 4: Pursued Tumor Types of Cancer Drugs at AACR 2017
Figure 5: Biomarker Development and Combination Therapies among Cancer Drugs at AACR 2017
Figure 6: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Cancer Drugs at AACR 2017
Figure 7: Drug Innovators Behind Cancer Drugs at AACR 2017
Figure 8: Pipeline Breakdown and Status of Startup Affiliated Drugs at AACR 2017
Figure 9: Compound Review of Startup Affiliated Drugs at AACR 2017
Figure 10: Target Analysis of Startup Affiliated Drugs at AACR 2017
Figure 11: Pursued Tumor Types of Startup Affiliated Drugs at AACR 2017
Figure 12: Biomarker Development and Combination Therapies among Startup Affiliated Drugs at AACR 2017
Figure 13: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Startup Affiliated Drugs at AACR 2017
Figure 14: Drug Innovators Behind Startup Affiliated Drugs at AACR 2017
Figure 15: Pipeline Breakdown and Status of Fierce 15 Affiliated Drugs at AACR 2017
Figure 16: Compound Review of Fierce 15 Affiliated Drugs at AACR 2017
Figure 17: Target Analysis of Fierce 15 Affiliated Drugs at AACR 2017
Figure 18: Pursued Tumor Types of Fierce 15 Affiliated Drugs at AACR 2017
Figure 19: Biomarker Development and Combination Therapies among Fierce 15 Affiliated Drugs at AACR 2017
Figure 20: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Fierce 15 Affiliated Drugs at AACR 2017
Figure 21: Drug Innovators Behind Fierce 15 Affiliated Drugs at AACR 2017
Figure 22: Pipeline Breakdown and Status of Orphan Drugs at AACR 2017
Figure 23: Compound Review of Orphan Drugs at AACR 2017
Figure 24: Target Analysis of Orphan Drugs at AACR 2017
Figure 25: Pursued Tumor Types of Orphan Drugs at AACR 2017
Figure 26: Biomarker Development and Combination Therapies among Orphan Drugs at AACR 2017
Figure 27 Breakthrough Drugs and Sales Data Figures Among Orphan Drugs at AACR 2017
Figure 28: Drug Innovators Behind Orphan Drugs at AACR 2017
Figure 29: Pipeline Breakdown and Status of Breakthrough Therapy Drugs at AACR 2017
Figure 30: Compound Review of Breakthrough Therapy Drugs at AACR 2017
Figure 31: Target Analysis of Breakthrough Therapy Drugs at AACR 2017
Figure 32: Pursued Tumor Types of Breakthrough Therapy Drugs at AACR 2017
Figure 33: Biomarker Development and Combination Therapies among Breakthrough Therapy Drugs at AACR 2017
Figure 34: Orphan Drugs and Sales Data Figures Among Breakthrough Therapy Drugs at AACR 2017
Figure 35: Drug Innovators Behind Breakthrough Therapy Drugs at AACR 2017
Figure 36: Pipeline Breakdown and Status of Cancer Vaccines at AACR 2017
Figure 37: Compound Review of Cancer Vaccines at AACR 2017
Figure 38: Target Analysis of Cancer Vaccines at AACR 2017
Figure 39: Pursued Tumor Types of Cancer Vaccines at AACR 2017
Figure 40: Biomarker Development and Combination Therapies among Cancer Vaccines at AACR 2017
Figure 41: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Cancer Vaccines at AACR 2017
Figure 42: Drug Innovators Behind Cancer Vaccines at AACR 2017
Figure 43: Pipeline Breakdown and Status of CAR/TCR Therapies at AACR 2017
Figure 44: Compound Review of CAR/TCR Therapies at AACR 2017
Figure 45: Target Analysis of CAR/TCR Therapies at AACR 2017
Figure 46: Pursued Tumor Types of CAR/TCR Therapies at AACR 2017
Figure 47: Biomarker Development and Combination Therapies among CAR/TCR Therapies at AACR 2017
Figure 48: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among CAR/TCR Therapies at AACR 2017
Figure 49: Drug Innovators Behind CAR/TCR Therapies at AACR 2017
Figure 50: Pipeline Breakdown and Status of Immune Checkpoint Drugs at AACR 2017
Figure 51: Compound Review of Immune Checkpoint Drugs at AACR 2017
Figure 52: Target Analysis of Immune Checkpoint Drugs at AACR 2017
Figure 53: Pursued Tumor Types of Immune Checkpoint Drugs at AACR 2017
Figure 54: Biomarker Development and Combination Therapies among Immune Checkpoint Drugs at AACR 2017
Figure 55: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Immune Checkpoint Drugs at AACR 2017
Figure 56: Drug Innovators Behind Immune Checkpoint Drugs at AACR 2017
Figure 57: Pipeline Breakdown and Status of Epigenetic Therapies at AACR 2017
Figure 58: Compound Review of Epigenetic Therapies at AACR 2017
Figure 59: Target Analysis of Epigenetic Therapies at AACR 2017
Figure 60: Pursued Tumor Types of Epigenetic Therapies at AACR 2017
Figure 61: Biomarker Development and Combination Therapies among Epigenetic Therapies at AACR 2017
Figure 62: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Epigenetic Therapies at AACR 2017
Figure 63: Drug Innovators Behind Epigenetic Therapies at AACR 2017
Figure 64: Pipeline Breakdown and Status of DNA Damage Response Drugs at AACR 2017
Figure 65: Compound Review of DNA Damage Response Drugs at AACR 2017
Figure 66: Target Analysis of DNA Damage Response Drugs at AACR 2017
Figure 67: Pursued Tumor Types of DNA Damage Response Drugs at AACR 2017
Figure 68: Biomarker Development and Combination Therapies among DNA Damage Response Drugs at AACR 2017
Figure 69: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among DNA Damage Response Drugs at AACR 2017
Figure 70: Drug Innovators Behind DNA Damage Response Drugs at AACR 2017
Figure 71: Pipeline Breakdown and Status of Protein Kinase Inhibitors at AACR 2017
Figure 72: Compound Review of Protein Kinase Inhibitors at AACR 2017
Figure 73: Target Analysis of Protein Kinase Inhibitors at AACR 2017
Figure 74: Pursued Tumor Types of Protein Kinase Inhibitors at AACR 2017
Figure 75: Biomarker Development and Combination Therapies among Protein Kinase Inhibitors at AACR 2017
Figure 76: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Protein Kinase Inhibitors at AACR 2017
Figure 77: Drug Innovators Behind Protein Kinase Inhibitors at AACR 2017
Figure 78: Pipeline Breakdown and Status of Cancer Antibodies at AACR 2017
Figure 79: Target Analysis of Cancer Antibodies at AACR 2017
Figure 80: Pursued Tumor Types of Cancer Antibodies at AACR 2017
Figure 81: Biomarker Development and Combination Therapies among Cancer Antibodies at AACR 2017
Figure 82: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Cancer Antibodies at AACR 2017
Figure 83: Drug Innovators Behind Cancer Antibodies at AACR 2017
Figure 84: Pipeline Breakdown and Status of Cancer Peptides at AACR 2017
Figure 85: Target Analysis of Cancer Peptides at AACR 2017
Figure 86: Pursued Tumor Types of Cancer Peptides at AACR 2017
Figure 87: Biomarker Development and Combination Therapies among Cancer Peptides at AACR 2017
Figure 88: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Cancer Peptides at AACR 2017
Figure 89: Drug Innovators Behind Cancer Peptides at AACR 2017
Figure 90: Pipeline Breakdown and Status of Nucleic Acid Therapies at AACR 2017
Figure 91: Target Analysis of Nucleic Acid Therapies at AACR 2017
Figure 92: Pursued Tumor Types of Nucleic Acid Therapies at AACR 2017
Figure 93: Biomarker Development and Combination Therapies among Nucleic Acid Therapies at AACR 2017
Figure 94: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Nucleic Acid Therapies at AACR 2017
Figure 95: Drug Innovators Behind Nucleic Acid Therapies at AACR 2017
Figure 96: Pipeline Breakdown and Status of Conjugated Drugs at AACR 2017
Figure 97: Compound Review of Conjugated Drugs at AACR 2017
Figure 98: Target Analysis of Conjugated Drugs at AACR 2017
Figure 99: Pursued Tumor Types of Conjugated Drugs at AACR 2017
Figure 100: Biomarker Development and Combination Therapies among Conjugated Drugs at AACR 2017
Figure 101: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Conjugated Drugs at AACR 2017
Figure 102: Drug Innovators Behind Conjugated Drugs at AACR 2017
1.2 List of Tables
Table 1: Pipeline Tably by Stage of Cancer Drugs at AACR 2017
Table 2: Pipeline Table by Compound Type of Cancer Drugs at AACR 2017
Table 3: Pipeline Table by Target of Cancer Drugs at AACR 2017
Table 4: Unique, First-in-class Drug Targets Belonging to One Drug Each
Table 5: Pipeline Table by Tumor Type of Cancer Drugs at AACR 2017
Table 6: Pipeline Table of Drugs with Biomarker Development and in Combination Therapies among Cancer Drugs at AACR 2017
Table 7: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Cancer Drugs at AACR 2017
Table 8: Pipeline Table by Drug Innovators Behind Cancer Drugs at AACR 2017
Table 9: Pipeline Table by Highest Development Stage of Startup Affiliated Drugs at AACR 2017
Table 10: Pipeline Table by Compound Type of Startup Affiliated Drugs at AACR 2017
Table 11: Pipeline Table by Target of Startup Affiliated Drugs at AACR 2017
Table 12: Pipeline Table by Tumor Type of Startup Affiliated Drugs at AACR 2017
Table 13: Pipeline Table of Startup Affiliated Drugs at AACR 2017 with Biomarker Development or In Combination Therapies
Table 14: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Startup Affiliated Drugs at AACR 2017
Table 15: Pipeline Table by Drug Innovators of Startup Affiliated Drugs at AACR 2017
Table 16: List of Identified Startup Companies Linked To Drugs at AACR 2017
Table 17: Pipeline Table by Highest Development Stage of Fierce 15 Affiliated Drugs at AACR 2017
Table 18: Pipeline Table by Compound Type of Fierce 15 Affiliated Drugs at AACR 2017
Table 19: Pipeline Table by Target of Fierce 15 Affiliated Drugs at AACR 2017
Table 20: Pipeline Table by Tumor Type of Fierce 15 Affiliated Drugs at AACR 2017
Table 21: Pipeline Table of Fierce 15 Affiliated Drugs at AACR 2017 with Biomarker Development or In Combination Therapies
Table 22: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Fierce 15 Affiliated Drugs at AACR 2017
Table 23: Pipeline Table by Drug Innovators of Fierce 15 Affiliated Drugs at AACR 2017
Table 24: List of Identified Fierce 15 Companies Linked To Drugs at AACR 2017
Table 25: Pipeline Table by Highest Development Stage of Orphan Drugs at AACR 2017
Table 26: Pipeline Table by Compound Type of Orphan Drugs at AACR 2017
Table 27: Pipeline Table by Target of Orphan Drugs at AACR 2017
Table 28: Pipeline Table by Tumor Type of Orphan Drugs at AACR 2017
Table 29: Pipeline Table of Orphan Drugs at AACR 2017 with Biomarker Development or In Combination Therapies
Table 30: Pipeline Table of Breakthrough Drugs and Drugs with Sales Data Figures Orphan Drugs at AACR 2017
Table 31: Pipeline Table by Drug Innovators of Orphan Drugs at AACR 2017
Table 32: Pipeline Table by Highest Developmental Stage of Breakthrough Therapy Drugs at AACR 2017
Table 33: Pipeline Table by Compound Type of Breakthrough Therapy Drugs at AACR 2017
Table 34: Pipeline Table by Target of Breakthrough Therapy Drugs at AACR 2017
Table 35: Pipeline Table by Tumor Type of Breakthrough Therapy Drugs at AACR 2017
Table 36: Pipeline Table of Breakthrough Therapy Drugs at AACR 2017 with Biomarker Development or In Combination Therapies
Table 37: Pipeline Table of Orphan Drugs and Drugs with Sales Data Figures Among Breakthrough Therapy Drugs at AACR 2017
Table 38: Pipeline Table by Drug Innovators of Breakthrough Therapy Drugs at AACR 2017
Table 39: Pipeline Table by Highest Development Stage of Cancer Vaccines at AACR 2017
Table 40: Pipeline Table by Compound Type of Cancer Vaccines at AACR 2017
Table 41: Pipeline Table by Target Cancer Vaccines at AACR 2017
Table 42: Pipeline Table by Tumor Type of Cancer Vaccines at AACR 2017
Table 43: Pipeline Table of Cancer Vaccines at AACR 2017 with Biomarker Development or In Combination Therapies
Table 44: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Cancer Vaccines at AACR 2017
Table 45: Pipeline Table by Drug Innovators of Cancer Vaccines at AACR 2017
Table 46: Pipeline Table by Highest Development Stage of CAR/TCR Therapies at AACR 2017
Table 47: Pipeline Table by Compound Type of CAR/TCR Therapies at AACR 2017
Table 48: Pipeline Table by Target of CAR/TCR Therapies at AACR 2017
Table 49: Pipeline Table by Tumor Type of CAR/TCR Therapies at AACR 2017
Table 50: Pipeline Table of CAR/TCR Therapies at AACR 2017 with Biomarker Development or In Combination Therapies
Table 51: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among CAR/TCR Therapies at AACR 2017
Table 52: Pipeline Table by Drug Innovators of CAR/TCR Therapies at AACR 2017
Table 53: Pipeline Table by Stage of Immune Checkpoint Drugs at AACR 2017
Table 54: Pipeline Table by Compound Type of Immune Checkpoint Drugs at AACR 2017
Table 55: Pipeline Table by Target of Immune Checkpoint Drugs at AACR 2017
Table 56: Pipeline Table by Tumor Type of Immune Checkpoint Drugs at AACR 2017
Table 57: Pipeline Table of Immune Checkpoint Drugs at AACR 2017 with Biomarker Development or In Combination Therapies
Table 58: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Immune Checkpoint Drugs at AACR 2017
Table 59: Pipeline Table by Drug Innovators of Immune Checkpoint Drugs at AACR 2017
Table 60: Pipeline Table by Highest Developmental Stage of Epigenetic Therapies at AACR 2017
Table 61: Pipeline Table by Compound Type of Epigenetic Therapies at AACR 2017
Table 62: Pipeline Table by Target of Epigenetic Therapies at AACR 2017
Table 63: Pipeline Table by Tumor Type of Epigenetic Therapies at AACR 2017
Table 64: Pipeline Table of Epigenetic Therapies at AACR 2017 with Biomarker Development or In Combination Therapies
Table 65: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Epigenetic Therapies at AACR 2017
Table 66: Pipeline Table by Drug Innovators of Epigenetic Therapies at AACR 2017
Table 67: Pipeline Table by Highest Development Stage of DNA Damage Response Drugs at AACR 2017
Table 68: Pipeline Table by Compound Type of DNA Damage Response Drugs at AACR 2017
Table 69: Pipeline Table by Target of DNA Damage Response Drugs at AACR 2017
Table 70: Pipeline Table by Tumor Type of DNA Damage Response Drugs at AACR 2017
Table 71: Pipeline Table of DNA Damage Response Drugs at AACR 2017 with Biomarker Development or In Combination Therapies
Table 72: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among DNA Damage Response Drugs at AACR 2017
Table 73: Pipeline Table by Drug Innovators of DNA Damage Response Drugs at AACR 2017
Table 74: Pipeline Table by Highest Development Stage of Protein Kinase Inhibitors at AACR 2017
Table 75: Pipeline Table by Compound Type of Protein Kinase Inhibitors at AACR 2017
Table 76: Pipeline Table by Target of Protein Kinase Inhibitors at AACR 2017
Table 77: Pipeline Table by Tumor Type of Protein Kinase Inhibitors at AACR 2017
Table 78: Pipeline Table of Protein Kinase Inhibitors at AACR 2017 with Biomarker Development or In Combination Therapies
Table 79: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Protein Kinase Inhibitors at AACR 2017
Table 80: Pipeline Table by Drug Innovators of Protein Kinase Inhibitors at AACR 2017
Table 81: Pipeline Table by Highest Development Stage of Cancer Antibodies at AACR 2017
Table 82: Pipeline Table by Target of Cancer Antibodies at AACR 2017
Table 83: Pipeline Table by Tumor Type of Cancer Antibodies at AACR 2017
Table 84: Pipeline Table of Cancer Antibodies at AACR 2017 with Biomarker Development or In Combination Therapies
Table 85: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Cancer Antibodies at AACR 2017
Table 86: Pipeline Table by Drug Innovators of Cancer Antibodies at AACR 2017
Table 87: Pipeline Table by Highest Developmental Stage of Cancer Peptides at AACR 2017
Table 88: Pipeline Table by Target of Cancer Peptides at AACR 2017
Table 89: Pipeline Table by Tumor Type of Cancer Peptides at AACR 2017
Table 90: Pipeline Table of Cancer Peptides at AACR 2017 with Biomarker Development or In Combination Therapies
Table 91: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Cancer Peptides at AACR 2017
Table 92: Pipeline Table by Drug Innovators of Cancer Peptides at AACR 2017
Table 93: Pipeline Table by Highest Development Stage of Nucleic Acid Therapies at AACR 2017
Table 94: Pipeline Table by Target of Nucleic Acid Therapies at AACR 2017
Table 95: Pipeline Table by Tumor Type of Nucleic Acid Therapies at AACR 2017
Table 96: Pipeline Table of Nucleic Acid Therapies at AACR 2017 with Biomarker Development or In Combination Therapies
Table 97: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Nucleic Acid Therapies at AACR 2017
Table 98: Pipeline Table by Drug Innovators of Nucleic Acid Therapies at AACR 2017
Table 99: Pipeline Table by Highest Development Stage of Conjugated Drugs at AACR 2017
Table 100: Pipeline Table by Compound Type of Conjugated Drugs at AACR 2017
Table 101: Pipeline Table by Target of Conjugated Drugs at AACR 2017
Table 102: Pipeline Table by Tumor Type of Conjugated Drugs at AACR 2017
Table 103: Pipeline Table of Conjugated Drugs at AACR 2017 with Biomarker Development or In Combination Therapies
Table 104: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Conjugated Drugs at AACR 2017
Table 105: Pipeline Table by Drug Innovators of Conjugated Drugs at AACR 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report